Commission will resume examination of new psychoactive substance, MCPP, in light of public concern after its initial decision not to follow up Europol-EMCDDA joint report

January 4, 2006

Brussels, 21 December 2005

Full text of Document 15832/05
Suite of documents 15832/05

19 December 2005

NOTE From: Horizontal Working Party on Drugs

No. prev. doc.: 14409/05 CORDROGUE 73

Subject: Follow-up to Europol-EMCDDA joint report on a new psychoactive substance; MCPP

1. In accordance with Article 5 of Council decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances, Europol/EMCDDA submitted in November 2005 a joint report on a new psychoactive substance 1-(3-chlorophenyl) piperazine (mCPP) (cf. doc. 14409/05 CORDROGUE 73).

2. The Horizontal Working Party examined this report at its meetings of 7 November 2005 and 8 December 2005. At the last meeting the Working Party agreed on the base of a room document of the Commission that no risk assessment should be carried out. However given the concern mCPP is causing and as provided for by the second indent of article 7.3 of before mentioned Council Decision the scope for further action, such as a scientific analysis, will be examined by the Commission in close cooperation with EMCDDA and EMEA.

3. The Commission will inform the Council on the results of this exam.

[Public Info Net automatically generates links to Council Register documents where an appropriately formatted document number is given. However, the document may not be available for public use and/or it may not be loaded on the Council Register yet.]

Council Register

You've reached your article limit.

Register to continue

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments
Register

Have your say

Log in or register to post comments